BD1 Ann Today:
• Option Agreement signed with the University of Liverpool to license two novel protein markers for development and commercialisation of a novel type 3c diabetes (T3cDM) blood test
• T3cDM accounts for up to 10% of new-onset diabetes cases, but it is currently underdiagnosed and poorly managed
• BARD1 is also developing blood tests for early detection of pancreatic cancer and an accurate T3cDM test could enable better management of T3cDM and stratification of people at risk of developing pancreatic cancer
- Forums
- ASX - Day Trading
- Morning trading April 13
BD1 Ann Today: • Option Agreement signed with the University of...
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online